Psychedelic Drug Developers Could Benefit From NIH Funding for Chronic Pain

Seeking AlphaApr 30 01:37

Atai Life Sciences Disclosed Dosing Of First Patient In Part 2 Of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive To SSRIs In Patients With Treatment Resistant Depression

Atai Life Sciences Disclosed Dosing Of First Patient In Part 2 Of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive To SSRIs In Patients With Treatment Resistant Depression

BenzingaApr 24 19:08

Is Atai Life Sciences (NASDAQ:ATAI) Using Debt In A Risky Way?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how

Simply Wall StApr 19 21:09

ATAI Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the publication of the

BenzingaApr 17 19:03

Atai Life Sciences CEO Florian Brand Spotlights Psychedelic Therapy Milestones and Upcoming Catalysts | NASDAQ:ATAI, ETR:9VC

Proactive InvestorsApr 16 00:21

ATAI Life Sciences(ATAI.US) Officer Sells US$66,231.85 in Common Stock

$ATAI Life Sciences(ATAI.US)$ Officer Kirpekar Sahil sold 35,801 shares of Common Stock on Apr 2, 2024 at an average price of $1.85 for a total value of $66,231.85.Source: Announcement What is stateme

Futu NewsApr 5 06:55